Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Baiden, Rita ^a   Oduro, Abraham ^b   Halidou, Tinto ^c   Gyapong, Margaret ^d   Sie, Ali ^e   Macete, Eusebio ^f   Abdulla, Salim ^g   Owusu Agyei, Seth ^h   Mulokozi, Abdunoor ^g   Adjei, Alex ^d   Sevene, Esperanca ^f   Compaoré, Guillaume ^e   Valea, Innocent ^c   Osei, Isaac ^b   Yawson, Abena ^h   Adjuik, Martin ^a   Akparibo, Raymond ^a   Ogutu, Bernhards ^a   Upunda, Gabriel Leonard ⁱ   Smith, Peter ^j   Binka, Fred ^a,k   more..

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Ghana)

^b NAVRONGO HEALTH RESEARCH CENTRE   (Ghana)

^c Nanoro Health Research Centre   (Burkina Faso)

^d Dodowa Health Research Centre   (Ghana)

^e CENTRE DE RECHERCHE EN SANTÉ DE NOUNA   (Burkina Faso)

^f Ministérioda Saúde   (Mozambique)

^g IFAKARA HEALTH INSTITUTE   (Tanzania)

^h KINTAMPO HEALTH RESEARCH CENTRE   (Ghana)

ⁱ Elderly and Children   (Tanzania)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^k UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Ghana)

more..

Author keywords

Cohort event monitoring; Electrocardiogram; Eurartesim ; QTc prolongation; Safety monitoring

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; PIPERAQUINE; QUINOLINE DERIVATIVE;

ACUTE GASTROENTERITIS; ADOLESCENT; ADULT; ANEMIA; ARTICLE; BURKINA FASO; CHILD; DEHYDRATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EAR DISEASE; ELECTROCARDIOGRAPHY; EYE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GHANA; HEART DISEASE; HEART PALPITATION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INNER EAR DISEASE; LONGITUDINAL STUDY; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; MOZAMBIQUE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PKA; PREGNANCY OUTCOME; PRESCHOOL CHILD; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; QTC INTERVAL; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SKIN DISEASE; TANZANIA; THORAX DISEASE; UROGENITAL TRACT DISEASE; VOMITING; YOUNG ADULT; AFRICA; AGED; CLINICAL TRIAL; COHORT ANALYSIS; DRUG COMBINATION; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH CARE FACILITY; HEART MUSCLE CONDUCTION SYSTEM; INFANT; MIDDLE AGED; NEWBORN; PATHOLOGY; VERY ELDERLY;

ADOLESCENT; ADULT; AFRICA; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH FACILITIES; HEART CONDUCTION SYSTEM; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALARIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES; YOUNG ADULT;

EID: 84928468640     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0664-9     Document Type: Article

References (31)

1. WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006 (assessed July 2014 at http://www.who.int/malaria/docs/treatmentGuidelines.2006.pdf).
2. WHO: World Malaria Report 2013. World Health Organization (Assessed June 2014 at www.who.int/malaria/publications/world-malaria-report-2013/en/
3. Kuemmerle A, Dodoo AN, Olsson S, Van Erps J, Burri C, Lalvani PS. Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring. Malar J. 2011;10:57.
4. Kabanywanyi AM, Mulure N, Migoha C, Malila A, Lengeler C, Schlienger R, et al. Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting. Malar J. 2010;9:205.
5. Bassi PU, Osakwe AI, Isah A, Suku C, Kalat M, Jalo I, et al. Safety of artemisinin-based combination therapies in Nigeria: a cohort event monitoring study. Drug Saf. 2013;36:747-56.
6. Dodoo AN, Fogg C, Nartey ET, Ferreira GL, Adjei GO, Kudzi W, et al. Profile of adverse events in patients receiving treatment for malaria in urban ghana: a cohort-event monitoring study. Drug Saf. 2014;37:433-48.
7. MSH. Strengthening Pharmaceutical Systems (SPS) Program. Safety of Medicines in Sub-Saharan Africa: Assessment of Pharmacovigilance Systems and their Performance; 2011. http://projects.msh.org/projects/sps/SPS-Documents/upload/SPS-FDA-PV-Report-March-2012.pdf.
8. Talisuna AO, Staedke SG, D'Alessandro U. Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J. 2006;5:50.
9. Thiam S, Ndiaye JL, Diallo I, Gatonga P, Fall FB, Diallo NE, et al. Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting. Malar J. 2013;12:54.
10. Sylla K, Abiola A, Tine RC, Faye B, Sow D, Ndiaye JL, et al. Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. BMC Infect Dis. 2013;13:598.
11. Ubben D, Poll EM. MMV in partnership: the Eurartesim® experience. Malar J. 2013;12:211.
12. Eurartesim®: EPAR - European Medicines Agency - Europa (assessed July 2014 at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001199/WC500118113.pdf)
13. Application for inclusion of dihydroartemisinin plus piperaquine (assessed July 2014 at http://www.who.int/selection-medicines/committees/expert/18/applications/D-Piperaquine.pdf)
14. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One. 2009;4:e7871.
15. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One. 2010;5:e11880.
16. White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7:549-58.
17. Borsini F, Crumb W, Pace S, Ubben D, Wible B, Yan GX, et al. In vitrocardiovasculareffects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother. 2012;56:3261-70.
18. EMA. Assessment report - Eurartesim (dihydroartemesinin/piperaquine phosphate). 2011. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/001199/WC500118116.pdf.
19. INDEPTH: INDEPTH Network. http://www.indepth-network.org (accessed on July 2014)
20. Binka FN, Morris SS, Ross DA, Arthur P, Aryeetey ME. Patterns of malaria morbidity and mortality in children in northern Ghana. Trans R Soc Trop Med Hyg. 1994;88:381-5.
21. Koram KA, Owusu-Agyei S, Fryauff DJ, Anto F, Atuguba F, Hodgson A, et al. Seasonal profiles of malaria infection, anaemia, and bednet use among age groups and communities in northern Ghana. Trop Med Int Health. 2003;8:793-802.
22. Baird JK, OwusuAgyei S, Utz GC, Koram K, Barcus MJ, Jones TR, et al. Seasonal malaria attack rates in infants and young children in northern Ghana. Am J Trop Med Hyg. 2002;66:280-6.
23. Sie A, Louis VR, Gbangou A, Müller O, Niamba L, Stieglbauer G, et al. The health and demographic surveillance system (HDSS) in Nouna, Burkina Faso, 1993-2007. Global Health Action. 2010;3:5284.
24. De Allegri M, Louis VR, Tiendrébeogo J, Souares A, Yé M, Tozan Y, et al. Moving towards universal coverage with malaria control interventions: achievements and challenges in rural Burkina Faso. Int J Health Plann Manage. 2013;28:102-21.
25. Nhacolo AQ, Nhalungo DA, Sacoor CN, Aponte JJ, Thompson R, Alonso P. Levels and trends of demographic indices in southern rural Mozambique: evidence from demographic surveillance in Manhiça district. BMC Public Health. 2006;6:291.
26. Dery DB, Brown C, Asante KP, Adams M, Dosoo D, Amenga-Etego S, et al. Patterns and seasonality of malaria transmission in the forest-savannah transitional zones of Ghana. Malar J. 2010;9:314.
27. Thertulien R, Manikhas GM, Dirix LY, Vermorken JB, Park K, Jain MM, et al. Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2012;69:341-50.
28. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. Version dated 12 May 2005. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf wesite
29. Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J. 2011;10:50.
30. Gargano N, Cenci F, Bassat Q. Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties. Trop Med Int Health. 2011;16:1466-73.
31. Moore BR, Benjamin JM, Salman S, Griffin S, Ginny E, Page-Sharp M, et al. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother. 2014;58:5784-94.